Feasibility and pathological response of TAS-118 + oxaliplatin as perioperative chemotherapy for patients with locally advanced gastric cancer (APOLLO-11).

Daisuke Takahari,Atsuo Takashima,Takako Eguchi Nakajima,Naoki Ishizuka,Manabu Ohashi,Hitoshi Katai,Shinya Mikami,Keisho Chin,Souya Nunobe,Miki Ito,Takeyuki Wada,Takashi Ogura,Takeshi Sano,Narikazu Boku,Kensei Yamaguchi

Feasibility and pathological response of TAS-118 + oxaliplatin as perioperative chemotherapy for patients with locally advanced gastric cancer (APOLLO-11).

2020

Daisuke Takahari
Atsuo Takashima
Takako Eguchi Nakajima
Naoki Ishizuka
Manabu Ohashi
Hitoshi Katai
Shinya Mikami
Keisho Chin
Souya Nunobe
Miki Ito
Takeyuki Wada
Takashi Ogura
Takeshi Sano
Narikazu Boku
Kensei Yamaguchi

351Background: TAS-118 is a novel oral agent, containing S-1 and leucovorin. In the SOLAR study (NCT02322593), TAS-118 + oxaliplatin (OHP) significantly improved overall survival compared to S-1 + ...

Keywords:

Cancer
Apollo
Oxaliplatin
Internal medicine
Chemotherapy
Medicine
Oncology
Pathological
Pathology
Perioperative
perioperative chemotherapy
oral agents
locally advanced
overall survival
pathological response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations